Row 31626

Row ID: 31626 | Dataset Entry | Axioma AXP Content Repository

Content Data

This page contains data entry 31626 from the Axioma AXP content repository. The structured data below represents the complete record for this entry.

"Norvo has a lot of interest in finding “impurities” in 3rd party product :). I take that with a grain of salt perhaps as they are trying to protect the business."

- while i can appreciate your position, I'm careful given it's not just Novo reporting quality issues with compounders, it's also the FDA reporting it. I've provided you a link to a news release from the National Association of Boards of Pharmacy (a licensure authority) advising member pharmacies that counterfeit products containing zero active ingredients or ingredients of questionable provenance/quality resulting in adverse events, have been found in the U.S. weight loss drug market. So is it possible Novo totally fabricated their claim, i suppose it could be if they did the testing in house and not via an independent 3rd party lab willing to put their name on the report. I just don't know enough about that to render an opinion one way or another, so in light of that I'm inclined to take Novo's word at face value given the FDA is likewise reporting quality issues with compounders. So it's not [just] Novo saying it, it's the FDA as well...

[Link: Natl Boards of Pharmacy ](https://nabp.pharmacy/news/blog/regulatory_news/fda-warns-of-fraud-pertaining-to-distribution-of-ozempic-other-medications/)

FieldValue
text "Norvo has a lot of interest in finding “impurities” in 3rd party product :). I take that with a grain of salt perhaps as they are trying to protect the business." - while i can appreciate your position, I'm careful given it's not just Novo reporting quality issues with compounders, it's also the FDA reporting it. I've provided you a link to a news release from the National Association of Boards of Pharmacy (a licensure authority) advising member pharmacies that counterfeit products containing …
label r/health
dataType comment
communityName r/Health
datetime 2024-05-21
username_encoded Z0FBQUFBQm5Lak1HaFNHNkNQTGQ3U21vVVQ3MHZFTEJtQkJuQjBvcXNBTUZUSEJVSU80Y05aWVhKamdjOUZTQVhwRGdmblRQU3VIcDVPY1pHWFJIMFlROUFSSW5GZ1p0Tnpua1NyQnRwb1gzZC1sTVlBUGNnTmc9
url_encoded Z0FBQUFBQm5Lak9XNkc3Q19Tc2VGb0c2RHVVSGlFVHRLYmdZYkNFTzFBNldaR0xacTFVcV93RDFXbm9UcXVQZ3ZnLXdIdC1aWE1Uc0JDTEVMSVNIaWdRQ1pKWmV4R2NsZmV0d1lvdm1tV2dRT0t0MmRPTndMU01NeHFic0RtUm13SktuZ3h6TmdMdWFzSHRKZXpHRkZ3dlkxNkI3LUFYdE92bnpPMkNBQnR0dmpvZmloQVNHbXAyY1BrOGJtQ05Gal9lMUpwQm1hY05DQWxtVV9Kb0tJYW9KUUlacG85UGc0dz09

Raw Record

{
  "text": "\"Norvo has a lot of interest in finding “impurities” in 3rd party product :). I take that with a grain of salt perhaps as they are trying to protect the business.\"\n\n- while i can appreciate your position, I'm careful given it's not just Novo reporting quality issues with compounders, it's also the FDA reporting it. I've provided you a link to a news release from the National Association of Boards of Pharmacy (a licensure authority) advising member pharmacies that counterfeit products containing zero active ingredients or ingredients of questionable provenance/quality resulting in adverse events, have been found in the U.S. weight loss drug market. So is it possible Novo totally fabricated their claim, i suppose it could be if they did the testing in house and not via an independent 3rd party lab willing to put their name on the report. I just don't know enough about that to render an opinion one way or another, so in light of that I'm inclined to take Novo's word at face value given the FDA is likewise reporting quality issues with compounders. So it's not [just] Novo saying it, it's the FDA as well...\n\n\n[Link: Natl Boards of Pharmacy ](https://nabp.pharmacy/news/blog/regulatory_news/fda-warns-of-fraud-pertaining-to-distribution-of-ozempic-other-medications/)",
  "label": "r/health",
  "dataType": "comment",
  "communityName": "r/Health",
  "datetime": "2024-05-21",
  "username_encoded": "Z0FBQUFBQm5Lak1HaFNHNkNQTGQ3U21vVVQ3MHZFTEJtQkJuQjBvcXNBTUZUSEJVSU80Y05aWVhKamdjOUZTQVhwRGdmblRQU3VIcDVPY1pHWFJIMFlROUFSSW5GZ1p0Tnpua1NyQnRwb1gzZC1sTVlBUGNnTmc9",
  "url_encoded": "Z0FBQUFBQm5Lak9XNkc3Q19Tc2VGb0c2RHVVSGlFVHRLYmdZYkNFTzFBNldaR0xacTFVcV93RDFXbm9UcXVQZ3ZnLXdIdC1aWE1Uc0JDTEVMSVNIaWdRQ1pKWmV4R2NsZmV0d1lvdm1tV2dRT0t0MmRPTndMU01NeHFic0RtUm13SktuZ3h6TmdMdWFzSHRKZXpHRkZ3dlkxNkI3LUFYdE92bnpPMkNBQnR0dmpvZmloQVNHbXAyY1BrOGJtQ05Gal9lMUpwQm1hY05DQWxtVV9Kb0tJYW9KUUlacG85UGc0dz09"
}
Explore Dataset Explore Row

Entry Information